• Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us
Sixsense News
Advertisement
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
Sixsense News
No Result
View All Result
Home Market

Icosavax begins early-stage study of bivalent RSV/hMPV vaccine IVX-A12

Sixsense News by Sixsense News
October 5, 2022
in Market
0


gorodenkoff

Icosavax (NASDAQ:ICVX) said it began a phase 1 trial of its combination bivalent vaccine candidate against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), IVX-A12 in older adults.

HMPV can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems, according to the U.S. CDC.

IVX-A12 consists of IVX-121, RSV prefusion F protein VLP vaccine candidate, and IVX-241, hMPV prefusion F protein VLP vaccine candidate, the company said in an Oct. 4 press release.

In June, Icosavax had reported data from a phase 1 trial of the RSV vaccine IVX-121.

Icosavax said that with the trial initiation, IVX-A12 becomes the first combination bivalent vaccine candidate against both RSV and hMPV to enter clinical stage, and the first candidate from the company’s VLP platform to receive IND (investigational new drug) authorization in the U.S.

“Not only is IVX-A12 Icosavax’s first combination bivalent VLP vaccine candidate, it is also the most advanced vaccine candidate against both RSV and hMPV in older adults, and the only clinical stage VLP in this space,” said Icosavax CEO Adam Simpson.

The company expects phase 1 topline interim results in mid-2023 and phase 2 start planned to follow in H2 2023.



Source link

Related articles

Chart Check: Breakout from a consolidation range makes this cement stock an attractive buy

March 31, 2023

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

March 31, 2023
Tags: beginsbivalentEarlyStageIcosavaxIVXA12RSVhMPVstudyvaccine

Related Posts

Chart Check: Breakout from a consolidation range makes this cement stock an attractive buy

by Sixsense News
March 31, 2023
0

UltraTech Cement hit a fresh 52-week high in the last week of March 2023 and technical indicators suggest that the...

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

by On The Market Podcast Presented by Fundrise
March 31, 2023
0

Last week, the Federal Reserve both surprisingly and unsurprisingly raised rates. For weeks leading up to this meeting, investors had...

China manufacturing growth eases in March to 51.9

by Sixsense News
March 31, 2023
0

The official NBS Manufacturing PMI declined to 51.9 in March of 2023 from February's near 11-year high of 52.6 but...

Asia FX muted, dollar sinks ahead of PCE inflation data By Investing.com

by Investing.com
March 31, 2023
0

© Reuters By Ambar Warrick Investing.com -- Most Asian currencies moved little on Friday as the dollar weakened on signs...

why is sensex rising: Sensex zooms 750 points on last day of FY23: Top 5 factors behind the rally

by Sixsense News
March 31, 2023
0

NEW DELHI: Led by buying across sectors, Sensex rallied up to 749 points while Nifty went near the 17,300 mark...

Load More

Car Battery Maintenance 101: How to Keep Your Car Running Smoothly

March 31, 2023

Chart Check: Breakout from a consolidation range makes this cement stock an attractive buy

March 31, 2023

Asian shares ride high in Q1 but keep vigil on inflation By Reuters

March 31, 2023

adani group stocks: All Adani Group stocks in green; Adani Power, NDTV hit 5% upper circuit

March 31, 2023

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

March 31, 2023

Asia-Pacific markets higher tracking gains on Wall Street buoyed by tech stocks

March 31, 2023
Sixsense News

© 2022 Sixsense News All Rights Reserved.

Navigate Site

  • Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us

Follow Us

No Result
View All Result
  • #3158 (no title)
  • Business
  • Economy
  • Finance
  • Fintech
  • Insurance
  • Market
  • Startups

© 2022 Sixsense News All Rights Reserved.